DelveInsight’s “Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast
Some of the key facts of the Low Grade Glioma Market Report:
The Low Grade Glioma market size was valued approximately USD 1 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2022, the market size of low-grade glioma (LGG) in Japan is below USD 100 million, with an anticipated increase during the forecast period from 2024 to 2034.
In April 2024, Day One Biopharmaceuticals obtained accelerated approval from the FDA for tovorafenib, to be marketed as Ojemda, for managing relapsed or refractory pediatric low-grade glioma in patients aged six months and above. As per Ojemda’s label, the oral kinase inhibitor is recommended for patients with verified BRAF fusion or rearrangement alterations, or a BRAF V600 mutation. The medication is available in tablet and oral suspension forms and should be administered once weekly.
In October 2023, Day One Biopharmaceuticals revealed that the FDA has approved its NDA for tovorafenib as a standalone treatment for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has prioritized the review and set a target action date under the Prescription Drug User Fee Act (PDUFA) for April 30, 2024.
In March 2023, The FDA has authorized the combination of TAFINLAR with MEKINIST, developed by Novartis, for pediatric patients aged 1 year and above diagnosed with low-grade glioma (LGG) and harboring a BRAF V600E mutation necessitating systemic treatment.
In the seven major markets (7MM), the overall incident population of low-grade glioma (LGG) was estimated to be around 9,000 cases in 2022 and is expected to rise over the forecast period.
In 2022, the United States had an estimated incident population of nearly 4,000 cases of low-grade glioma (LGG). This accounts for the largest portion of the incident population of LGG in the seven major markets (7MM), constituting approximately 40% of the total.
In 2022, approximately 3,000 patients in the United States were identified with IDH mutation, while nearly 300 were diagnosed with BRAF V600E cases.
Key Low Grade Glioma Companies: Day One Biopharmaceuticals, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
Key Low Grade Glioma Therapies: Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
The Low Grade Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.
Low Grade Glioma Overview
Low-grade Gliomas (LGG) constitute a diverse category of primary brain tumors commonly found in younger, otherwise healthy individuals. Typically, these tumors exhibit a relatively slow progression and extended survival rates compared to high-grade gliomas.
Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/low-grade-glioma-market
Low Grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Low Grade Glioma Epidemiology Segmentation:
The Low Grade Glioma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Low Grade Glioma
Prevalent Cases of Low Grade Glioma by severity
Gender-specific Prevalence of Low Grade Glioma
Diagnosed Cases of Episodic and Chronic Low Grade Glioma
Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast
Low Grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Low Grade Glioma Therapies and Key Companies
Tovorafenib: Day One Biopharmaceuticals
Vinblastine: The Hospital for Sick Children
Everolimus: University of California
DAY101: Day One Biopharmaceuticals
DS-1001b: Daiichi Sankyo Co.
Mebendazole: Julie Krystal
dabrafenib: Novartis
Vorasidenib: Servier
Mirdametinib: SpringWorks Therapeutics
AB-218: AnHeart Therapeutics
BGB-290: Beigene
Infigratinib: Helsinn
FT-2102 (Olutasidenib): Forma Therapeutics
Vinblastine + Bevacizumab: Hoffmann-La Roche, and others
Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape
Low Grade Glioma Market Strengths
Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.
Low Grade Glioma Market Opportunities
Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.
Scope of the Low Grade Glioma Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Low Grade Glioma Unmet Needs, KOL’s views, Analyst’s views, Low Grade Glioma Market Access and Reimbursement
To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Low Grade Glioma Market Report Introduction
2. Executive Summary for Low Grade Glioma
3. SWOT analysis of Low Grade Glioma
4. Low Grade Glioma Patient Share (%) Overview at a Glance
5. Low Grade Glioma Market Overview at a Glance
6. Low Grade Glioma Disease Background and Overview
7. Low Grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Low Grade Glioma
9. Low Grade Glioma Current Treatment and Medical Practices
10. Low Grade Glioma Unmet Needs
11. Low Grade Glioma Emerging Therapies
12. Low Grade Glioma Market Outlook
13. Country-Wise Low Grade Glioma Market Analysis (2020–2034)
14. Low Grade Glioma Market Access and Reimbursement of Therapies
15. Low Grade Glioma Market Drivers
16. Low Grade Glioma Market Barriers
17. Low Grade Glioma Appendix
18. Low Grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
